logo
logo
Sign in

The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18%, claims Roots Analysis

avatar
ella turner
The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18%, claims Roots Analysis

With the approval of HUMULIN®, the first genetically modified drug, scientific community has made significant progress in developing gene edited therapies based on programmable nucleases, such as ZFNs, TALENs, EMNs and CRISPR

 

London

 

Roots Analysis has announced the addition of “Gene-Editing Beyond CRISPR: Focus on ZFN, TALENs and Meganucleases Market, 2021-2035” report to its list of offerings.

 

The ability of gene editing solutions to directly target and modify genomic sequences has greatly expedited the progress of gene editing therapies into clinical stages. The future opportunity within the gene editing market has been segmented across [A] type of payment (upfront payment and milestone payment) and [B] geography (North America, Europe, and Asia Pacific and rest of the world).

 

To order this 150+ page report, which features 100+ figures and 5+ tables, please visit

https://www.rootsanalysis.com/reports/gene-editing-market.html


To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/gene-editing-market/request-sample.html

Key Questions Answered

§ Who are the players engaged in the development of gene editing therapies beyond CRISPR?

§ Which are the key drugs being developed across early and late stages of development?

§ Which companies are actively involved in conducting clinical trials for ZFNs, TALENs and Meganucleases based therapies?

§ What is the focus area of various publications related to ZFNs, TALENs and Meganucleases based therapies?

§ What kind of partnership models are commonly adopted by industry stakeholders?

§ What is the trend of capital investments in the gene editing beyond CRISPR market?

§ How has the intellectual property landscape related to ZFNs, TALENs and Meganucleases based therapies evolved over the years?

§ How is the current and future opportunity, related to ZFNs, TALENs and Meganucleases based therapies, likely to be distributed across key market segments?

 

The financial opportunity within the gene editing technologies market has been analyzed across the following key geographical regions, including: 

  • North America
  • Europe
  • Asia Pacific

 

 

The research includes detailed profiles of key players (listed below) engaged in the development of gene editing technologies; each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.

§ Allogene Therapeutics

§ bluebird bio

§ Cellectis

§ Cytovia Therapeutics

§ Iovance Biotherapeutics

§ Precision Biosciences

§ Sangamo Therapeutics

 

For additional details, please visit

https://www.rootsanalysis.com/reports/gene-editing-market.html or email [email protected]

 

You may also be interested in the following titles:

1.   CRISPR based Therapeutic Market by Type of Therapy, 2021-2030

2.   Gene Editing Services Market- Focus on CRISPR, 2019-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

 

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

[email protected]

collect
0
avatar
ella turner
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more